Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders

  • Lauren P. McLaughlin
  • Catherine M. Bollard
  • Michael Keller
Immune Deficiency and Dysregulation (D Huston and C Kuo, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Immune Deficiency and Dysregulation


Primary immunodeficiency disorders (PID) are a group of inborn errors of immunity with a broad range of clinical severity but often associated with recurrent and serious infections. While hematopoietic stem cell transplantation (HSCT) can be curative for some forms of PID, chronic and/or refractory viral infections remain a cause of morbidity and mortality both before and after HSCT. Although antiviral pharmacologic agents exist for many viral pathogens, these are associated with significant costs and toxicities and may not be effective for increasingly drug-resistant pathogens. Thus, the emergence of adoptive immunotherapy with virus-specific T lymphocytes (VSTs) is an attractive option for addressing the underlying impaired T cell immunity in many PID patients. VSTs have been utilized for PID patients following HSCT in many prior phase I trials, and may potentially be beneficial before HSCT in patients with chronic viral infections. We review the various methods of generating VSTs, clinical experience using VSTs for PID patients, and current limitations as well as potential ways to broaden the clinical applicability of adoptive immunotherapy for PID patients.


Primary immunodeficiency Cytotoxic T lymphocytes Adoptive immunotherapy Antiviral therapy Hematopoietic stem cell transplantation 



We would like to thank the staffs of the Divisions of Allergy and Immunology and Blood and Marrow Transplantation at Children’s National Medical Center, our collaborators at the Cell and Gene Therapy center at Baylor College of Medicine and other institutions, the Children’s Research Institute, and the Jeffrey Modell Foundation for their support of this work.

Compliance with Ethical Standards

Conflict of Interest

Drs. McLaughlin, Bollard, and Keller declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bousfiha AA, Jeddane L, Ailal F, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol. 2013;33(6):1078–87.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015.Google Scholar
  3. 3.
    Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res. 2011;49(1–3):25–43.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol. 2014;26(6):454–70.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602–610 e601-611.Google Scholar
  6. 6.
    Worth AJ, Booth C, Veys P. Stem cell transplantation for primary immune deficiency. Curr Opin Hematol. 2013;20(6):501–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Cuellar-Rodriguez J, Gea-Banacloche J, Freeman AF, et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood. 2011;118(13):3715–20.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cuellar-Rodriguez J, Freeman AF, Grossman J, et al. Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency. Biol Blood Marrow Transplant. 2015;21(6):1037–45.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Notarangelo LD, Gambineri E, Badolato R. Immunodeficiencies with autoimmune consequences. Adv Immunol. 2006;89:321–70.CrossRefPubMedGoogle Scholar
  10. 10.
    Milner JD, Vogel TP, Forbes L, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125(4):591–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hutspardol S, Essa M, Richardson S, et al. Significant transplantation-related mortality from respiratory virus infections within the first One hundred days in children after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(10):1802–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Odek C, Kendirli T, Dogu F, et al. Patients with primary immunodeficiencies in pediatric intensive care unit: outcomes and mortality-related risk factors. J Clin Immunol. 2014;34(3):309–15.CrossRefPubMedGoogle Scholar
  13. 13.•
    Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. 2014;37(5):434–46. This study demonstrates the impact of active infections on survival of HSCT in patients with severe combined immunodeficiency.CrossRefGoogle Scholar
  14. 14.
    Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lugthart G, Oomen MA, der Zijde CM J-v, et al. The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution. Biol Blood Marrow Transplant. 2015;21(2):293–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Biron KK. Antiviral drugs for cytomegalovirus diseases. Anticancer Res. 2006;71(2–3):154–63.Google Scholar
  17. 17.
    Sellar RS, Peggs KS. Management of multidrug-resistant viruses in the immunocompromised host. Br J Haematol. 2012;156(5):559–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol. 2010;47(2):124–32.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Brown JA, Boussiotis VA. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol. 2008;127(3):286–97.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2010;10(3):337–51.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hromas R, Cornetta K, Srour E, Blanke C, Broun ER. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood. 1994;84(5):1689–90.PubMedGoogle Scholar
  23. 23.
    Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2011;11(4):473–87.CrossRefPubMedGoogle Scholar
  24. 24.
    Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119(11):2644–56.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hanley PJ, Keller MD, Martin Manso M, et al. A phase 1 perspective: multivirus-specific T-cells from both cord blood and bone marrow transplant donors. Cytotherapy. 2016;18(6):S8.CrossRefGoogle Scholar
  26. 26.
    Bollard CM, Heslop HE. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016;127(26):3331–40.CrossRefPubMedGoogle Scholar
  27. 27.
    O’Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E. Virus-specific T-cell banks for ‘off the shelf’ adoptive therapy of refractory infections. Bone Marrow Transplant. 2016.Google Scholar
  28. 28.
    Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038–44.CrossRefPubMedGoogle Scholar
  29. 29.•
    Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238–41. The first report of adoptive immunotherapy with Cytomegalovirus-specific CD8+ cytotoxic T cell clones to restore CMV-specific immunity after HSCT.CrossRefPubMedGoogle Scholar
  30. 30.
    Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330(17):1185–91.CrossRefPubMedGoogle Scholar
  31. 31.
    Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9–13.CrossRefPubMedGoogle Scholar
  32. 32.
    Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331(10):679–80.CrossRefPubMedGoogle Scholar
  33. 33.
    Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202(3):379–86.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.••
    Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160–6. This group demonstrated not only that multivirus-specific T cells can be generated using a single culture method but also that these T cell products are safe and effective when used to treat immunocompromised patients.CrossRefPubMedGoogle Scholar
  35. 35.
    Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20(8):1622–32.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Neudorfer J, Schmidt B, Huster KM, et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods. 2007;320(1–2):119–31.CrossRefPubMedGoogle Scholar
  37. 37.
    Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2005;128(4):503–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Feucht J, Joachim L, Lang P, Feuchtinger T. Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation. Klin Padiatr. 2013;225(3):164–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Cohen JI. Primary immunodeficiencies associated with EBV disease. Curr Top Microbiol Immunol. 2015;390(Pt 1):241–65.PubMedGoogle Scholar
  40. 40.••
    Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35. This study demonstrated long term persistence of EBV-specific T-cells following HSCT.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549–55.PubMedGoogle Scholar
  42. 42.
    Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283–92.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Bao L, Cowan MJ, Dunham K, et al. Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections. J Immunother. 2012;35(3):293–8.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.••
    Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra283. Using a rapid culture method, this group showed that VSTs that recognize 12 immunogenic antigens from 5 viruses (Epstein-Barr virus, adenovirus, cytomegalovirus, BK virus, and Human Herpesvirus 6) can be manufactured in less than two weeks. While only 14 of the 48 VST products had activity against antigens from all 5 viruses, the authors showed that viral specificity was related to prior viral exposure of the VST donors rather than a limitation in the manufacturing protocol. Safety and efficacy was demonstrated in 11 patients who had a 94% response rate.CrossRefGoogle Scholar
  45. 45.••
    Naik S, Nicholas SK, Martinez CA, et al. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016. This is the largest review of VSTs used in patients with primary immunodeficiencies that showed the safety and efficiacy of VSTs in this population.Google Scholar
  46. 46.••
    Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–23. This is the largest phase II study of partially-HLA matched third-party VST therapy for treatment of viral infections following HSCT.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Wynn RF, Arkwright PD, Haque T, et al. Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol. 2005;6(5):344–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Vickers MA, Wilkie GM, Robinson N, et al. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol. 2014;167(3):402–10.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64–76.CrossRefPubMedGoogle Scholar
  50. 50.
    Qasim W, Gilmour K, Zhan H, et al. Interferon-gamma capture T cell therapy for persistent adenoviraemia following allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2013;161(3):449–52.CrossRefPubMedGoogle Scholar
  51. 51.
    Creidy R, Moshous D, Touzot F, et al. Specific T cells for the treatment of cytomegalovirus and/or adenovirus in the context of hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2016;138(3):920–4. e923.CrossRefPubMedGoogle Scholar
  52. 52.
    Feucht J, Opherk K, Lang P, et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood. 2015;125(12):1986–94.CrossRefPubMedGoogle Scholar
  53. 53.
    Melenhorst JJ, Leen AM, Bollard CM, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116(22):4700–2.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Crooks BN, Taylor CE, Turner AJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant. 2000;26(10):1097–102.CrossRefPubMedGoogle Scholar
  56. 56.
    Karron RA, Collins PL. Parainfluenza viruses. In: Knipe DM, Howley PM, editors. Fields virology, vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 996–1023.Google Scholar
  57. 57.
    McLaughlin LP, Lang H, Williams E, et al. Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. Cytotherapy. 2016Google Scholar
  58. 58.
    Ma CK, Clancy L, Deo S, Blyth E, Micklethwaite KP, Gottlieb DJ. Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy. Cytotherapy. 2016Google Scholar
  59. 59.
    Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118(10):2653–5.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Hanson EP, Monaco-Shawver L, Solt LA, et al. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol. 2008;122(6):1169–77. e1116.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397–406.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Cruz CR, Lam S, Hanley PJ, et al. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013;174(1):89–96.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133(4):1134–41.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Smith LL, Wright BL, Buckley RH. Successful treatment of disseminated BCG in a patient with severe combined immunodeficiency. J Allergy Clin Immunol Pract. 2015;3(3):438–40.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Lauren P. McLaughlin
    • 1
    • 2
  • Catherine M. Bollard
    • 1
    • 2
    • 3
  • Michael Keller
    • 1
    • 3
  1. 1.Center for Cancer and Immunology ResearchChildren’s National Health SystemWashingtonUSA
  2. 2.Division of Blood and Marrow TransplantationChildren’s National Health SystemWashingtonUSA
  3. 3.Division of Allergy/Immunology Center for Cancer and Immunology Research Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency DisordersChildren’s National Health SystemWashingtonUSA

Personalised recommendations